Skip to main content
MAYNE PHARMA GROUP LIMITED logo

MAYNE PHARMA GROUP LIMITED — Investor Relations & Filings

Ticker · MYX ISIN · AU000000MYX0 LEI · 549300VIRDEN0N4MJG59 ASX Manufacturing
Open in API
Filings indexed 1,119 across all filing types
Latest filing 2019-11-24 Director's Dealing
Country AU Australia
Listing ASX MYX

About MAYNE PHARMA GROUP LIMITED

https://www.maynepharma.com

Mayne Pharma Group Limited is a specialty pharmaceutical company focused on the development and commercialization of branded and generic medicines. The company operates through specialized segments including Women's Health and Dermatology. Its Women's Health portfolio features innovative contraceptive solutions, while the Dermatology division provides a broad range of treatments for various skin conditions. Beyond its product portfolio, the company provides contract development and manufacturing services (CDMO), leveraging proprietary drug delivery technologies to produce complex oral and topical dosage forms. The organization focuses on high-growth specialty markets, aiming to deliver differentiated therapeutic options and improve patient outcomes through technical excellence and strategic commercialization.

Recent filings

Filing Released Lang Actions
Final Director's Interest Notice 2 pages 87.1KB
Director's Dealing Classification · 100% confidence The document is titled 'Appendix 3Z Final Director’s Interest Notice' and references ASX listing rule 3.19A.3 and section 205G of the Corporations Act. It details the director's relevant interests in securities, including holdings and indirect interests, and notes the date the director ceased to be a director. This is a report of personal share transactions or holdings by a company director, which aligns with the definition of Director's Dealing filings. The document length is short and focused solely on director interests, with no financial statements or broader company information. Therefore, the appropriate classification is Director's Dealing (DIRS).
2019-11-24 English
2019 AGM Chairman's Address 5 pages 115.0KB
AGM Information Classification · 95% confidence The document is an ASX announcement titled '2019 Annual General Meeting' and includes the Chairman's address, introduction of board members, discussion of company performance, strategic updates, and operational highlights. It references the formal meeting agenda including voting on resolutions. The content is typical of materials presented during an Annual General Meeting, including management and board remarks, but does not contain full financial statements or detailed financial analysis typical of an Annual Report (10-K) or Interim Report (IR). The document is lengthy (over 12,000 characters) and contains detailed AGM-related content rather than just an announcement of a report publication. Therefore, it fits the category of AGM Information (AGM-R).
2019-11-21 English
2019 AGM CEO's Speech 7 pages 138.4KB
AGM Information Classification · 95% confidence The document is an ASX announcement dated around November 2019, detailing the CEO's address at the Annual General Meeting (AGM) of Mayne Pharma. It includes strategic updates, trading performance for the first four months of the fiscal year 2020, product pipeline information, and outlook commentary. The content is typical of presentations or materials shared during an AGM, focusing on business updates and future plans rather than full financial statements or regulatory filings. There is no indication that this is a full Annual Report (10-K), Interim Report (IR), or Earnings Release (ER). The document is lengthy (15,000 characters) and contains detailed narrative and strategic commentary, consistent with AGM Information. Therefore, the appropriate classification is AGM Information (AGM-R).
2019-11-21 English
2019 AGM Presentation 15 pages 692.1KB
AGM Information Classification · 100% confidence The document is titled 'Annual General Meeting 22 November 2019' and contains detailed presentations including Chairman's and CEO's addresses, financial performance overview for FY19, business updates, product pipeline, market analysis, and outlook. It is a presentation material shared during the Annual General Meeting, as indicated by the title and content style. The document does not contain full financial statements or detailed annual report data but rather a summary and forward-looking statements typical of AGM presentations. Therefore, it fits the category of AGM Information (AGM-R). The document length and content confirm it is the presentation itself, not just an announcement of a report.
2019-11-21 English
Results of Meeting 2 pages 169.2KB
Declaration of Voting Results & Voting Rights Announcements Classification · 95% confidence The document is dated 22 November 2019 and is addressed to the ASX Limited Company Announcements office. It provides detailed voting results for resolutions passed at the Mayne Pharma Group Limited Annual General Meeting (AGM) held on the same date. The content includes proxy votes, percentages for and against each resolution, and whether each resolution was carried or not. The document references compliance with Listing Rule 3.13.2 and section 251AA of the Corporations Act, which relate to disclosure of voting results. There is no indication that this is the full AGM report or presentation, but rather the official announcement of the voting results from the AGM. The document length is relatively short (2562 characters), consistent with a voting results announcement rather than a full report. Therefore, the document fits the category of Declaration of Voting Results & Voting Rights Announcements (DVA).
2019-11-21 English
Mayne Pharma continues expansion of dermatology pipeline 1
Capital/Financing Update Classification · 90% confidence The document is an ASX announcement dated 19 November 2019 about Mayne Pharma licensing rights to a generic topical dermatology product. It discusses a business development related to product licensing and pipeline expansion, with no financial statements, regulatory certifications, or detailed financial data. The document is relatively short (2381 characters) and serves as a corporate update rather than a formal financial report or regulatory filing. It does not fit categories like Annual Report, Interim Report, Earnings Release, or Audit Report. It is not a call transcript or management report. It is a capital/financing update or business development announcement related to product licensing and pipeline expansion, which aligns best with Capital/Financing Update (CAP).
2019-11-18 English

Browse filings by year

20 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.